Welcome!
Raffles Medical Group (RMG)
Broker's Calls
RHB lowers Raffles Medical's TP to $1.60 on declining revenue and cost headwinds
RHB analyst Shekhar Jaiswal also reduced his earnings estimates for the group by 3% each for the FY2023 and FY2024.
October 17, 2022
Broker's Calls
High inflation could benefit healthcare industry based on historical trends: DBS
DBS analyst Rachel Tan says the pricing power of healthcare service providers could offset the inflationary cost pressures.
August 18, 2022
Broker's Calls
Analysts mostly lift TPs on Raffles Medical Group on the back of record 1HFY2022 results
The analysts have also mostly raised their earnings or earnings per share estimates for the FY2022.
August 11, 2022
Results
Raffles Medical Group sees 51.3% surge in 1HFY2022 earnings of $59.7 mil
Based on the current conditions, the directors expect the group to remain profitable for the rest of the year.
August 01, 2022
Broker's Calls
Broker's digest: MLT, Raffles Medical Group, iFast Corporation, Sembcorp Industries
See what the analysts have to say this week.
July 29, 2022
Broker's Calls
Broker's Digest: Advanced Info Service, SGX, Raffles Medical Group, EC World REIT, Jason Marine Group
See what the analysts have to say about these counters.
July 15, 2022
Broker's Calls
CGS-CIMB upgrades Raffles Medical Group to 'add' with lower TP of $1.27
The new target price is pegged to an FY2023 EV/EBITDA of 16x, 0.5 standard deviation below its five-year historical mean.
July 12, 2022
Broker's Calls
RHB lowers Raffles Medical's TP to $1.50 due to slower ramp up in China operations
Despite the lower TP, RHB analyst Shekhar Jaiswal sees 2022 as a "transition year" for the group. Here's why.
June 20, 2022
Broker's Calls
Uncertainty on Chinese healthcare may cause overhang on stocks like IHH Healthcare, Q&M Dental and Raffles Medical
Will China's crackdown extend to the healthcare sector?
March 16, 2022
Broker's Calls
CGS-CIMB, PhillipCapital remain 'neutral' on Raffles Medical Group on weaker FY2022 prospects
Analysts from CGS-CIMB and PhillipCapital have also lowered their target price estimates to $1.33 and $1.27 respectively.
February 24, 2022